Detect cancer earlier, from a single tube of blood
SPOT-MAS is an AI-powered blood testing platform that detects cancer-associated DNA signals, offering solutions from multi-cancer early detection to tailored, cancer-specific screening to make cancer screening more accessible and support earlier detection at a routine visit.
SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation*
(*) Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review. SPOT-MAS is a screening test, not a diagnostic test.
PLATFORM TECHNOLOGY
One blood draw, read three layers
SPOT-MAS profiles cell-free DNA across genetics, epigenetics and fragmentomics. The DNASphere.AI engine analyzes all three together to detect a ctDNA signal and predict where it comes from.
01
Single blood draw
One tube during a routine healthcare visit.
02
Extraction and library prep
cfDNA is extracted and prepared for sequencing.
03
Multi-omics analysis
- Genomic
- Epigenetics
- Fragmentomics
04
AI-powered analysis
DNASphere.AI applies machine and deep learning models.
05
Detection and origin
ctDNA signal detected, with predicted tumor origin.
| K-DETEK performance (n=9,024) | Sensitivity | Specificity | PPV | NPV | TOO |
|---|---|---|---|---|---|
| Including pre-cancerous findings | 78.1% | 99.8% | 58.1% | 99.9% | 84% |
| Cancerous cases only | 70.8% | 99.7% | 39.5% | 99.9% | 52.9% |
PRODUCT PORTFOLIO
One platform, multiple clinical approach
SPOT-MAS 10: multi-cancer early detection
Multi-cancer Early Detection
Analyzes multi-omics features of 10 cancer types, supported by a dataset spanning 75 subtypes. Seven of the ten (marked) currently have no standard-of-care screening program.
Breast
Lung
Colorectum
Stomach
Liver-Biliary tract
Ovary
Pancreas
Esophagus
Head & Neck
Endometrium
SPOT-MAS Lung
Single-cancer early detection
Lung-specific DNA features for lung cancer screening and triage.
SPOT-MAS EVA
Gynecological cancer early detection
Molecular precision screening & triage for cervical and endometrial cancers.
SPOT-MAS CRC
Single-cancer early detection
Colorectum-specific DNA features for colorectal cancer screening.
SPOT-MAS 360
Multi-cancer early detection
Hereditary Screening
Designed for comprehensive cancer and hereditary risk disease screening.
SCIENTIFIC EVIDENCE
Backed by science. Driven by data.
JOURNAL OF CLINICAL ONCOLOGY
2026
Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations.
The first large-scale real-world evidence from Asia supporting the robustness and clinical utility of SPOT-MAS as a complementary screening strategy, particularly in LMICs lacking accessible national screening programs.
BMC MEDICINE
2025
Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults
This study aims to validate the clinical utility of a multimodal non-invasive circulating tumor DNA (ctDNA)-based MCED test, SPOT-MAS (Screening for the Presence Of Tumor by DNA Methylation And Size).
ELIFE
2023
Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
This study provides insights into the early detection of malignancies with noninvasive methods by developing a framework, which assesses methylation, CNA, and other genomic features.
RESOURCES
Resources
Healthcare Professional Leaflet
Evaluation Of A Multimodal Ctdna-based Assay For Detection Of Aggressive Cancers Lacking Standard Screening Tests
Pioneering a Tumor-Specific Methylation Atlas (TSMA) to Identify Tissue of Origin (TOO) in Multi-Cancer Early Detection
Effective Clinical Follow-Up for ctDNA Multi-Cancer Early Detection Test: A Peer-Reviewed Study of Post-Test Standard Operating Procedure and Real-Life Results
Gene Solutions x Pioneering Paths: The Science Behind Multi-Cancer Early Detection
SPOT-MAS is a multi-cancer early detection test developed by Gene Solutions
Understanding SPOT-MAS test results
ctDNA screening against colorectal cancer
SPOT-MAS EVA HCP Flyer
Patient Leaflet
Gene Solutions x Pioneering Paths: The Science Behind Multi-Cancer Early Detection
Understanding SPOT-MAS test results
SPOT-MAS is a multi-cancer early detection test developed by Gene Solutions
ctDNA screening against colorectal cancer
SPOT-MAS EVA Patient Leaflet
NEWS & INSIGHTS
Featured News
GLOBAL OPERATIONS
Our Global Footprint
Singapore
Vietnam
Hong Kong
Philippines
India
Brazil
CAP-Accredited Laboratory
CAP-Accredited Laboratory
Indonesia
Taiwan
Malaysia
Thailand
Türkiye
USA
Explore
Related Platforms
PRENATAL HEALTHCARE PLATFORM
triSure
Comprehensive prenatal screening for selected fetal genetic conditions and maternal health risks, from just 10 mL of maternal blood.
PRECISION ONCOLOGY PLATFORM
K-TRACK / K-4CARE
World-class genomic profiling and cancer monitoring powered by multi-omics.
REFERENCES
1. Nguyen, L.H.D. et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC Med 23, 90 (2025). doi:10.1186/s12916 025 03929-y.
2. These 10 cancer types accounted for 56.2% of total new incidences and 59.9% of total mortality (WHO GLOBOCAN South-East Asia Report, 2022).
3. These include a case-control study published in eLife Science, the K DETEK clinical validation study published in BMC Medicine, and a real-world experience report of 10,577 tests conducted across South-East Asia (Vietnam, Singapore, Malaysia, Thailand, Indonesia, and the Philippines) reported in ESMO Annals of Oncology
4. Nguyen, Trong Hieu, et al. "Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization." Elife 12 (2023): RP89083.
5. Thien Nguyen, Chi Van, et al. "Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests." Future Oncology (2024): 1-11.
DISCLAIMER
This test is meant to add to, not replace, your regular cancer screening test